Case 24: Progressive Glioma

Ian Law; Jonathan F. Carlsen; Benedikte Hasselbalch

doi:10.1007/978-3-030-83598-9_24

Case 24: Progressive Glioma

Ian Law, Jonathan F. Carlsen, Benedikte Hasselbalch

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › peer review

Abstract

The use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.

Originalsprog	Engelsk
Titel	Clinical Nuclear Medicine in Neurology : An Atlas of Challenging Cases
Redaktører	Andrea Varrone, Silvia Morbelli, Valentina Garibotto
Forlag	Springer
Publikationsdato	2022
Sider	119-123
Kapitel	24
ISBN (Trykt)	978-3-030-83597-2
ISBN (Elektronisk)	978-3-030-83598-9
DOI	https://doi.org/10.1007/978-3-030-83598-9_24
Status	Udgivet - 2022

Adgang til dokumentet

10.1007/978-3-030-83598-9_24

Citationsformater

@inbook{c35b3092095146febd6ea4ddca6bd0f3,

title = "Case 24: Progressive Glioma",

abstract = "The use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.",

author = "Ian Law and Carlsen, {Jonathan F.} and Benedikte Hasselbalch",

year = "2022",

doi = "10.1007/978-3-030-83598-9_24",

language = "English",

isbn = "978-3-030-83597-2",

pages = "119--123",

editor = "Andrea Varrone and Silvia Morbelli and Valentina Garibotto",

booktitle = "Clinical Nuclear Medicine in Neurology",

publisher = "Springer",

address = "Switzerland",

}

TY - CHAP

T1 - Case 24: Progressive Glioma

AU - Law, Ian

AU - Carlsen, Jonathan F.

AU - Hasselbalch, Benedikte

PY - 2022

Y1 - 2022

N2 - The use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.

AB - The use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.

U2 - 10.1007/978-3-030-83598-9_24

DO - 10.1007/978-3-030-83598-9_24

M3 - Book chapter

SN - 978-3-030-83597-2

SP - 119

EP - 123

BT - Clinical Nuclear Medicine in Neurology

A2 - Varrone, Andrea

A2 - Morbelli, Silvia

A2 - Garibotto, Valentina

PB - Springer

ER -